CHICAGO -- For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved significantly versus chemotherapy with the addition of tumor treating fields (TTFields).

Median OS increased from 14.2 months with gemcitabine-paclitaxel chemotherapy to 16.2 months with the addition of TTFields. One-year survival also improved from 60.2% to 68.1% with the electric-field therapy. Progression-free survival (PFS) did not improve, but did reduce the risk of distant metastasis. TTFields therapy was associated with a 6-month increase in pain-free survival, a key quality-of-life metric for patients with advanced pancreatic cancer.

No treatment-related deaths occurred with TTFields, and no new safety signals emerged, reported Vincent Picozzi, MD, of Virginia Maso

See Full Page